iBio Inc. [AMEX: IBIO] stock went on an upward path that rose over 16.87% on Monday, amounting to a one-week price increase of more than 9.36%. The company report on December 28, 2020 that iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer.
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020.
“We are thrilled to have Dr. Brenner join our team,” said Tom Isett, Chairman & CEO of iBio. “Given his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to assist iBio with a similar transformation. Notably, he also brings a track-record of effective new target search and evaluation, as well as establishing productive collaborations.”.
Over the last 12 months, IBIO stock rose by 580.00%. The one-year iBio Inc. stock forecast points to a potential upside of 25.2. The average equity rating for IBIO stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $398.09 million, with 216.01 million shares outstanding and 181.60 million shares in the current float. Compared to the average trading volume of 13.58M shares, IBIO stock reached a trading volume of 31181268 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on iBio Inc. [IBIO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBIO shares is $2.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBIO stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for iBio Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 22, 2021. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on June 26, 2020, representing the official price target for iBio Inc. stock.
The Average True Range (ATR) for iBio Inc. is set at 0.15, with the Price to Sales ratio for IBIO stock in the period of the last 12 months amounting to 209.52. The Price to Book ratio for the last quarter was 3.82, with the Price to Cash per share for the same quarter was set at 0.39.
IBIO Stock Performance Analysis:
iBio Inc. [IBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.36. With this latest performance, IBIO shares gained by 71.56% in over the last four-week period, additionally sinking by -57.88% over the last 6 months – not to mention a rise of 580.00% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBIO stock in for the last two-week period is set at 67.31, with the RSI for the last a single of trading hit 71.53, and the three-weeks RSI is set at 62.88 for iBio Inc. [IBIO]. The present Moving Average for the last 50 days of trading for this stock 1.3840, while it was recorded at 1.6900 for the last single week of trading, and 1.9576 for the last 200 days.
Insight into iBio Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and iBio Inc. [IBIO] shares currently have an operating margin of -854.88. iBio Inc.’s Net Margin is presently recorded at -1003.60.
Return on Total Capital for IBIO is now -23.97, given the latest momentum, and Return on Invested Capital for the company is -28.32. Return on Equity for this stock declined to -55.65, with Return on Assets sitting at -26.35. When it comes to the capital structure of this company, iBio Inc. [IBIO] has a Total Debt to Total Equity ratio set at 58.12. Additionally, IBIO Total Debt to Total Capital is recorded at 36.76, with Total Debt to Total Assets ending up at 34.94. Long-Term Debt to Equity for the company is recorded at 57.13, with the Long-Term Debt to Total Capital now at 36.13.
Reflecting on the efficiency of the workforce at the company, iBio Inc. [IBIO] managed to generate an average of -$4,109,750 per employee. Receivables Turnover for the company is 0.57 with a Total Asset Turnover recorded at a value of 0.03.iBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 16.70 and a Current Ratio set at 16.80.
iBio Inc. [IBIO] Insider Position Details
There are presently around $30 million, or 8.10% of IBIO stock, in the hands of institutional investors. The top three institutional holders of IBIO stocks are: BLACKROCK INC. with ownership of 5,448,105, which is approximately 25.874% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 2,675,662 shares of the stock with an approximate value of $5.0 million in IBIO stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $2.8 million in IBIO stock with ownership of nearly 113.212% of the company’s market capitalization.
Positions in iBio Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 61 institutional holders increased their position in iBio Inc. [AMEX:IBIO] by around 6,384,863 shares. Additionally, 23 investors decreased positions by around 658,919 shares, while 9 investors held positions by with 8,961,410 shares. The mentioned changes placed institutional holdings at 16,005,192 shares, according to the latest SEC report filing. IBIO stock had 30 new institutional investments in for a total of 1,565,584 shares, while 13 institutional investors sold positions of 522,537 shares during the same period.